Favorable Coverage Decisions Broaden Access to This Minimally
Invasive Treatment That Provides Rapid Relief and Recovery from Symptoms
WAYNE, Pa.--(BUSINESS WIRE)--Feb. 14, 2019--
NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX)
focused on addressing unmet needs in the field of urology, today
announced that Humana, one of the nation’s largest private health
insurers, is now providing insurance coverage for the UroLift®
System, a minimally invasive in-office treatment that provides rapid
relief and recovery from the symptoms of benign prostatic hyperplasia
(BPH).1,2
Humana insures more than 9.2 million lives through their commercial and
Medicare Advantage products. With more than 3.5 million Medicare
Advantage members, Humana is also one of the country's largest
administrators of Medicare Advantage plans.
NeoTract also announced that an additional 90,000 lives are now covered
for the UroLift System by Motion Picture Industry Pension & Health Plans
(MPI), which is administered by Anthem Blue Cross – This is an
encouraging step forward as Anthem Blue Cross is the only independent
licensee of the Blue Cross Blue Shield Association not currently
allowing member access to the UroLift System procedure. With these
recent coverage decisions, a large majority of insured men in America
now have access to the UroLift System procedure using their health
insurance benefits.
“These coverage decisions are a major testament to the clinical benefits
of the UroLift System for treating Benign Prostatic Hyperplasia (BPH), a
common condition that significantly impacts the overall health of men
with symptomatic BPH as well as the quality of life for those men and
their partners,” said Dave Amerson, president of Teleflex Interventional
Urology business unit. “We are pleased to see the continued acceptance
of the UroLift System as a standard-of-care therapy for patients with
symptomatic BPH. This coverage milestone will expand lasting and durable
symptom relief to millions of men, allowing them to return to a
healthier and better quality of life.”
BPH, also known as enlarged prostate, is a common condition marked by
bothersome urinary symptoms that can cause loss of productivity,
depression, interrupted sleep, and decreased quality of life.3
BPH affects over 40 million men in the United States alone.4
If left untreated, the condition can worsen over time and cause
permanent bladder damage.5
The UroLift System is the only minimally invasive treatment option that
has been shown to provide rapid and durable symptomatic and urinary flow
rate improvement without causing sexual dysfunction. *1,6-9
The Prostatic Urethral Lift procedure is recommended for the treatment
of BPH in both the American Urological Association and European
Association of Urology clinical guidelines.
*No instances of new, sustained erectile or ejaculatory dysfunction.
About the UroLift® System
The FDA-cleared UroLift System is a proven, minimally invasive
technology for treating lower urinary tract symptoms due to benign
prostatic hyperplasia (BPH). The UroLift permanent implants, delivered
during a minimally invasive transurethral outpatient procedure, relieve
prostate obstruction and open the urethra directly without cutting,
heating, or removing prostate tissue. Clinical data from a pivotal
206-patient randomized controlled study showed that patients with
enlarged prostate receiving UroLift implants reported rapid and durable
symptomatic and urinary flow rate improvement without compromising
sexual function. *1,9 Patients also experienced a significant
improvement in quality of life. Over 80,000 men have been treated with
the UroLift System in the U.S. Most common adverse events reported
include hematuria, dysuria, micturition urgency, pelvic pain, and urge
incontinence. Most symptoms were mild to moderate in severity and
resolved within two to four weeks after the procedure. The UroLift
System is available in the U.S., Europe, Australia, Canada, Mexico and
South Korea. Learn more at www.UroLift.com.
About NeoTract | Teleflex Interventional Urology
A wholly owned subsidiary of Teleflex Incorporated, the Interventional
Urology Business Unit is dedicated to developing innovative, minimally
invasive and clinically effective devices that address unmet needs in
the field of urology. Our initial focus is on improving the standard of
care for patients with BPH using the UroLift System, a minimally
invasive permanent implant system that treats symptoms while preserving
normal sexual function. Learn more at www.NeoTract.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit www.Teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson
RCI®, LMA®, Pilling®, Rusch®,
UroLift® and Weck® – trusted brands united by a
common sense of purpose.
*No instances of new, sustained erectile or ejaculatory dysfunction
1Roehrborn,
J Urology 2013 LIFT Study
2 Shore, Can J Urol 2014 Local
Study
3 Speakman et al. 2014 BJUI International
4
NeoTract US Market Model estimates for 2018 based on IQVIA Health Drug
and Procedure data
5 Tubaro et al. 2003 Drugs Aging
6
AUA BPH Guidelines 2003, 2010, 2018
7 Naspro, Eur Urol
2009
8 Montorsi, J Urol 2008
9 McVary, J
Sex Med 2016
MAC00969-01 Rev A
View source version on businesswire.com: https://www.businesswire.com/news/home/20190214005045/en/
Source: Teleflex Incorporated
For Teleflex Incorporated:
Jake Elguicze, 610.948.2836
Treasurer
and Vice President, Investor Relations
Media:
Nicole Osmer, 650.454.0504
nicole@healthandcommerce.com